Drugs / Dersimelagon
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05241535 | Jan → Feb 2022 | — | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04793295 | Mar 2021 → Feb 2022 | — | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04656795 | Dec 2020 → Dec 2021 | impaired renal function disease | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04116476 | Aug 2019 → Feb 2021 | — | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03688022 | Oct → Dec 2018 | — | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03503266 | Mar → May 2018 | — | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02834442 | Jul 2016 → Jun 2017 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT04440592 | Feb 2021 → Jan 2024 | diffuse cutaneous systemic sclerosis | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03520036 | Jul 2018 → Sep 2019 | erythropoietic protoporphyria | Tanabe Pharma America, Inc. | Completed | Met primary |
| Phase 33 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT06144840 | Dec 2023 → Apr 2026 | X-linked erythropoietic protoporphyria | Tanabe Pharma America, Inc. | Completed | Met primary |
| Phase 3 | NCT05005975 | Aug 2021 → Dec 2027 expected | X-linked erythropoietic protoporphyria | Tanabe Pharma America, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT04402489 | Jun 2020 → Dec 2021 | X-linked erythropoietic protoporphyria | Tanabe Pharma America, Inc. | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06994286 Comparator | Jun → Jul 2025 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-03-30 | Tanabe Pharma Corporation | Results Tanabe Pharma Announces Positive Data from Phase 3 INSPIRE Study of Dersimelagon in EPP and XLP tanabe-pharma.com ↗
Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director, CEO: Akihisa Harada, hereinafter "Tanabe Pharma") today announced detailed results from the Phase 3 INSPIRE study of investigational oral dersimelagon in people living with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). |
| 2026-01-15 | Tanabe Pharma Corporation | Results MT-7117 Demonstrates Positive Topline Results in Development for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) tanabe-pharma.com ↗
MT-7117 Demonstrates Positive Topline Results in Development for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) |
| 2019-11-11 | Tanabe Pharma Corporation | Results Mitsubishi Tanabe Pharma Corporation Announces Results of the MT-7117 ENDEAVOR Study for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP) tanabe-pharma.com ↗
ENDEAVOR met its primary endpoint of change from baseline in average daily time (minutes) to first prodromal symptom associated with sunlight exposure between 1 hour post sunrise and 1 hour pre -sunset at Week 16. |
All press releases naming this drug 6 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dersimelagon | “Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT-7117), an Oral Melanocortin-1 Receptor Agonist.” PMID 38746989 ↗ May 20242“Dersimelagon is a new, orally administered, selective melanocortin 1 receptor agonist that increases levels of skin eumelanin.” PMID 37043653 ↗ Apr 2023 |
| Known as | DERSIMELAGON PHOSPHATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802160 ↗ |
| Known as | Dersimelagon phosphoric acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802160 ↗ |
| Known as | MT-7117 | “Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT-7117), an Oral Melanocortin-1 Receptor Agonist.” PMID 38746989 ↗ May 2024 |
| Known as | MT-7117 phosphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802160 ↗ |
| Action | Activate | “selective agonist of the melanocortin-1 receptor” PMID 39887900 ↗ Feb 20251“Melanocortin receptor 1 agonist” CHEMBL4802160 ↗ |
| Modality | Small molecule | — CHEMBL4802160 ↗ |
| Route | Oral | “single oral dose” NCT03503266 ↗ |
| Target | MC1R | “Melanocortin receptor 1 agonist” CHEMBL4802160 ↗ |